Vigabatrin

규격

60643-86-9CAS 번호

270-929-6EC 번호

4-aminohex-5-enoic acidIUPAC 명칭

C6H11NO2화학식

129.16 g/mol분자량

vigabatrin; 60643-86-9; 68506-86-5; Sabril; 4-Amino-5-hexenoic acid; gamma-Vinyl GABA; Vigabatrine; gamma-Vinyl-GABA; 5-Hexenoic acid, 4-amino-; gamma Vinyl GABA; Vigabatrina; Vigabatrinum; Vigabatrinum [Latin]; MDL-71754; RMI-71754; gamma-Vinyl-gamma-Aminobutyric Acid; CPP-109; DTXSID4041153; VIGAFYDE; MDL 71,754; (+-)-gamma-Vinyl GABA; VINYL GAMMA-AMINOBUTYRIC ACID; GR120KRT6K; DTXCID2021153; CHEBI:63638; Vigabatrinum (Latin); gamma Vinyl gamma Aminobutyric Acid; VIGADRONE; VIGPODER; RefChem:901854; vigabatrin for oral solution; N03AG04; 4-aminohex-5-enoic acid; 4-Aminohexenoic acid; GVG; CPP109; (+/-)-Vigabatrin; MFCD00274577; (+/-)-gamma-Vinyl-GABA; CHEMBL89598; Vigabatrine [French]; (+/-)-4-aminohex-5-enoic acid; Vigabatrina [Spanish]; NCGC00016087-06; Sabrilex; 4-aminohex-5-enoic acid/S(+)-Gamma-VIGABATRIN; Sabril (TN); Vigabatrin [USAN:INN:BAN]; RMI-71890; MDL 71754; RMI 71754; (+/-)-gamma-Vinyl GABA; Hexenoic acid, 4-amino; SR-01000075653; UNII-GR120KRT6K; 4-Amino-hex-5-enoic acid; Kigabeq; Vigabatrin?; Vigabatrin CRS; (1)-4-Aminohex-5-enoic acid; CPP 109; Vigabatrin [INN]; Prestwick_837; -Vinyl-GABA; EINECS 270-929-6; .gamma.-vinyl GABA; .gamma.-Vinyl-GABA; Spectrum_000368; SpecPlus_000664; VIGABATRIN [MI]; (y)-gamma-Vinyl GABA; VIGABATRIN [JAN]; Prestwick0_000501; Prestwick1_000501; Prestwick2_000501; Prestwick3_000501; Spectrum3_001825; Vigafyde (oral solution); VIGABATRIN [USAN]; (?)-gamma-Vinyl GABA; VIGABATRIN [VANDF]; Biomol-NT_000247; V 8261; VIGABATRIN [MART.]; VIGABATRIN [USP-RS]; VIGABATRIN [WHO-DD]; Lopac0_001277; M071754; SCHEMBL26714; BSPBio_000421; BSPBio_003469; KBioSS_000848; Vigabatrin (JAN/USP/INN); orb363932; (A+/-)-gamma-Vinyl GABA; DivK1c_006760; SPECTRUM1502036; (+/-)-?-Vinyl GABA; SPBio_002342; ( inverted exclamation markA)-4-aminohex-5-enoic acid; BPBio1_000465; BPBio1_000925; GTPL4821; orb1224487; orb1310910; VIGABATRIN [ORANGE BOOK]; Vinyl .gamma.-aminobutyric Acid; HSDB 8395; KBio1_001704; KBio2_000848; KBio2_003416; KBio2_005984; KBio3_002973; VIGABATRIN, (+/-)-; VIGABATRIN [EP MONOGRAPH]; GLXC-05977; HMS1569F03; HMS2094M21; HMS2096F03; HMS3263P16; VIGABATRIN [USP MONOGRAPH]; Tox21_110301; Tox21_501277; BDBM50118886; EBC-06162; EX-A11014; HB0868; AKOS015854596; CCG-205350; CS-0791; DB01080; FV61480; LP01277; SDCCGSBI-0051243.P004; .gamma.-Vinyl-.gamma.-aminobutyric acid; NCGC00016087-03; NCGC00016087-04; NCGC00016087-05; NCGC00016087-07; NCGC00016087-08; NCGC00016087-09; NCGC00016087-11; NCGC00016087-22; NCGC00024802-02; NCGC00024802-03; NCGC00024802-04; NCGC00024802-05; NCGC00024802-06; NCGC00261962-01; AS-11778; HY-15399; SBI-0051243.P003; ( inverted question mark)-gamma-Vinyl GABA; CAS-68506-86-5; DB-117820; AB00053309; EU-0101277; NS00000678; T0128; C07500; D00535; EN300-245587; AB00053309_04; Q421663; SR-01000075653-1; SR-01000075653-4; SR-01000075653-6; BRD-A07893380-001-01-6; BRD-A07893380-213-01-7; Z1255431434; Vigabatrin, European Pharmacopoeia (EP) Reference Standard; Vigabatrin, United States Pharmacopeia (USP) Reference Standard동의어